Leucine
Assembly Line
Leucine reaps $7M in series A funds to advance AI digital twin platform for manufacturing
Leucine reeled in $7 million in series A funding that will be used scale up its AI-generated digital twin platform designed to help drug manufacturers more easily navigate the complex landscape of regulatory compliance. The funding round was led by Ecolab with participation from existing investors Pravega Ventures, Axilor Ventures and Techstars.
The New York City-based company, which was founded in 2019, is focused on using digital twins in its Compliance Cloud platform to alleviate drug development workflow bottlenecks caused by paper-based records and legacy systems.